Log in

NASDAQ:ENDP - Endo International Stock Price, Forecast & News

$3.09
+0.02 (+0.65 %)
(As of 04/3/2020 08:00 AM ET)
Today's Range
$3.03
Now: $3.09
$3.29
50-Day Range
$2.28
MA: $4.63
$6.55
52-Week Range
$1.97
Now: $3.09
$8.55
Volume2.88 million shs
Average Volume7.15 million shs
Market Capitalization$700.90 million
P/E RatioN/A
Dividend YieldN/A
Beta1.51
Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States, Canada, and internationally. The company operates through three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals, and International Pharmaceuticals. The U.S. Generic Pharmaceuticals segment offers solid oral extended-release, solid oral immediate-release, abuse-deterrent products, liquids, semi-solids, patches, powders, ophthalmics, sprays, and sterile injectables, as well as products for the pain management, urology, central nervous system disorders, immunosuppression, oncology, women's health, and cardiovascular disease markets. The U.S. Branded Pharmaceuticals segment provides XIAFLEX for the treatment of Dupuytren's contracture and Peyronie's diseases; SUPPRELIN LA for central precocious puberty treatment; TESTOPEL, a long-acting implantable pellet for the treatment of central precocious puberty; NASCOBAL, a nasal spray to treat vitamin B12 deficiency; and AVEED for the treatment of hypogonadism. This segment also offers pain management products, such as PERCOCET, VOLTAREN Gel, and LIDODERM; TESTIM Gel for the treatment of endogenous testosterone; and FORTESTA Gel for hypogonadism treatment. The International Pharmaceuticals segment offers specialty pharmaceutical products in various therapeutic areas comprising attention deficit hyperactivity disorder, pain, women's health, and oncology. It sells its branded pharmaceuticals and generics directly to specialty physicians, retailers, clinics, government agencies, doctors, retail and specialty pharmacies, and specialty distributors, as well as through wholesale drug distributors. Endo International plc was founded in 1920 and is headquartered in Dublin, Ireland.
Read More
Endo International logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Current SymbolNASDAQ:ENDP
CUSIP29264F20
Phone011-353-1268-2000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.91 billion
Cash Flow$5.24 per share
Book Value($3.82) per share

Profitability

Net Income$-422,640,000.00

Miscellaneous

Employees3,172
Market Cap$700.90 million
Next Earnings Date5/14/2020 (Estimated)
OptionableOptionable

Receive ENDP News and Ratings via Email

Sign-up to receive the latest news and ratings for ENDP and its competitors with MarketBeat's FREE daily newsletter.


Endo International (NASDAQ:ENDP) Frequently Asked Questions

How has Endo International's stock been impacted by COVID-19 (Coronavirus)?

Endo International's stock was trading at $3.89 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, ENDP shares have decreased by 20.6% and is now trading at $3.09. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Endo International?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Endo International in the last year. There are currently 2 sell ratings, 5 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Endo International.

When is Endo International's next earnings date?

Endo International is scheduled to release its next quarterly earnings announcement on Thursday, May 14th 2020. View our earnings forecast for Endo International.

How were Endo International's earnings last quarter?

Endo International PLC (NASDAQ:ENDP) issued its earnings results on Wednesday, February, 26th. The company reported $0.74 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.57 by $0.17. The business earned $764.80 million during the quarter, compared to analyst estimates of $730.15 million. Endo International had a negative return on equity of 84.43% and a negative net margin of 14.50%. The company's revenue for the quarter was down 2.7% on a year-over-year basis. During the same period in the previous year, the business posted $0.75 earnings per share. View Endo International's earnings history.

What guidance has Endo International issued on next quarter's earnings?

Endo International issued an update on its FY20 earnings guidance on Wednesday, February, 26th. The company provided earnings per share (EPS) guidance of $2.15-2.40 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.25. The company issued revenue guidance of $2.72-2.92 billion, compared to the consensus revenue estimate of $2.90 billion.

What price target have analysts set for ENDP?

9 brokers have issued 1-year price targets for Endo International's stock. Their forecasts range from $3.00 to $15.00. On average, they expect Endo International's share price to reach $6.86 in the next twelve months. This suggests a possible upside of 122.0% from the stock's current price. View analysts' price targets for Endo International.

Has Endo International been receiving favorable news coverage?

Press coverage about ENDP stock has been trending very negative this week, according to InfoTrie Sentiment. The research firm scores the sentiment of news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Endo International earned a media sentiment score of -3.3 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near future. View the latest news aboutEndo International.

Are investors shorting Endo International?

Endo International saw a decline in short interest in the month of March. As of March 13th, there was short interest totaling 28,532,100 shares, a decline of 8.0% from the February 27th total of 31,020,000 shares. Based on an average daily trading volume, of 6,554,700 shares, the short-interest ratio is currently 4.4 days. Currently, 12.8% of the company's shares are short sold. View Endo International's Current Options Chain.

Who are some of Endo International's key competitors?

What other stocks do shareholders of Endo International own?

Who are Endo International's key executives?

Endo International's management team includes the following people:
  • Mr. Paul V. Campanelli, Pres, CEO & Director (Age 57)
  • Mr. Blaise Coleman, Exec. VP & CFO (Age 45)
  • Mr. Terrance J. Coughlin, Exec. VP & COO (Age 53)
  • Mr. Matthew Joseph Maletta, Exec. VP & Chief Legal Officer (Age 47)
  • Mr. Antonio R. Pera, Pres of Par Pharmaceutical (Age 62)

What is Endo International's stock symbol?

Endo International trades on the NASDAQ under the ticker symbol "ENDP."

How do I buy shares of Endo International?

Shares of ENDP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Endo International's stock price today?

One share of ENDP stock can currently be purchased for approximately $3.09.

How big of a company is Endo International?

Endo International has a market capitalization of $700.90 million and generates $2.91 billion in revenue each year. The company earns $-422,640,000.00 in net income (profit) each year or $2.38 on an earnings per share basis. Endo International employs 3,172 workers across the globe. View additional information about Endo International.

What is Endo International's official website?

The official website for Endo International is http://www.endo.com/.

How can I contact Endo International?

Endo International's mailing address is First Floor Minerva House Simmonscourt Road Ballsbridge, Dublin L2, 19355. The company can be reached via phone at 011-353-1268-2000 or via email at [email protected]


MarketBeat Community Rating for Endo International (NASDAQ ENDP)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  905 (Vote Outperform)
Underperform Votes:  805 (Vote Underperform)
Total Votes:  1,710
MarketBeat's community ratings are surveys of what our community members think about Endo International and other stocks. Vote "Outperform" if you believe ENDP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ENDP will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/3/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel